Figure 5
Effects of GW9662 on rosiglitazone-induced adiponectin expression and antidepressant- and anxiolytic-like behavioral responses in wild-type mice. (a1) Adipose adiponectin mRNA and protein levels. Left, adiponectin mRNA levels (pretreatment: F(1,16)=3.641, P<0.05; treatment: F(1,16)=2.050, P>0.05; interaction: F(1,19)=8.506, P<0.05). Right, representative immunoblots and quantification of adiponectin protein expression (pretreatment: F(1,16)=7.783, P<0.05; treatment: F(1,16)=4.895, P<0.05; interaction: F(1,16)=4.678, P<0.05). n=5 per group. (a2) Plasma adiponectin. Representative immunoblots and quantification of plasma adiponectin levels (pretreatment: F(1,16)=5.017, P<0.05; treatment: F(1,16)=1.640, P>0.05; interaction: F(1,16)=10.705, P<0.05). n=5 per group. (b) Forced swim test. Left, latency to immobility (pretreatment: F(1,28)=9.754, P<0.01; treatment: F(1,28)=6.690, P<0.05; interaction: F(1,28)=7.102, P<0.05). Right, immobility time (pretreatment: F(1,28)=17.939, P<0.001; treatment: F(1,28)=16.331, P<0.001; interaction: F(1,28)=14.190, P<0.001). n=8 per group. (c) Elevated plus-maze test. Left, percentage of open arm entries (pretreatment: F(1,32)=2.237, P>0.05; treatment: F(1,32)=4.234, P<0.05; interaction: F(1,32)=6.571, P<0.05). Middle, percentage of open arm time (pretreatment: F(1,32)=1.584, P>0.05; treatment: F(1,32)=3.356, P>0.05; interaction: F(1,32)=4.854, P<0.05). Right, total arm entries (pretreatment: F(1,32)=0.417, P>0.05; treatment: F(1,32)=0.031, P>0.05; interaction: F(1,32)=0.996, P>0.05). n=9 per group. (d) Novelty-suppressed feeding test. Left, latency to feed (pretreatment: F(1,32)=1.004, P>0.05; treatment: F(1,32)=5.059, P<0.05; interaction: F(1,32)=1.390, P>0.05). Right, home-cage food consumption in 5 min after the test (pretreatment: F(1,32)=0.304, P>0.05; treatment: F(1,32)=0.123, P>0.05; interaction: F(1,32)=0.003, P>0.05). n=9 per group. *P<0.05, **P<0.01, ***P<0.001 compared with the Vehicle+Vehicle treatment group; #P<0.05, ##P<0.01, ###P<0.001 compared with the Vehicle+Rosiglitazone treatment group. Data are shown as mean±s.e.m.
